CY1113012T1 - Λιποσωμικες φαρμακοτεχνικες μορφες παραγοντων ανθρακυκλινης και αναλογων κυτιδινης - Google Patents

Λιποσωμικες φαρμακοτεχνικες μορφες παραγοντων ανθρακυκλινης και αναλογων κυτιδινης

Info

Publication number
CY1113012T1
CY1113012T1 CY20121100616T CY121100616T CY1113012T1 CY 1113012 T1 CY1113012 T1 CY 1113012T1 CY 20121100616 T CY20121100616 T CY 20121100616T CY 121100616 T CY121100616 T CY 121100616T CY 1113012 T1 CY1113012 T1 CY 1113012T1
Authority
CY
Cyprus
Prior art keywords
cytidine analog
liposomic
carbonic
cylinder
pharmaceutical forms
Prior art date
Application number
CY20121100616T
Other languages
English (en)
Inventor
Lawrence Mayer
Sharon Johnstone
Troy Harasym
Original Assignee
Celator Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celator Pharmaceuticals, Inc. filed Critical Celator Pharmaceuticals, Inc.
Publication of CY1113012T1 publication Critical patent/CY1113012T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/797—Lipid particle
    • Y10S977/798—Lipid particle having internalized material
    • Y10S977/799—Containing biological material
    • Y10S977/801—Drug

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)

Abstract

Συνθέσεις οι οποίες περιλαμβάνουν παράγοντα ανθρακυκλίνης και ένα ανάλογο κυτιδίνης είναι ενθυλακωμένες σε ένα λιποσωμικό φορέα. Ο προτιμώμενος παράγων ανθρακυκλίνης επιλέγεται από την ομάδα νταουνορουμπικίνης, ντοξορουμπικίνης και ινταρουμπικίνης, ενώ το προτιμώμενο ανάλογο κυτιδίνης επιλέγεται από την ομάδα κυταραμπίνης, τζεμσιταμπίνης ή 5-αζακυτιδίνης. Ο συνδυασμός του παράγοντα ανθρακυκλίνης και αναλόγου κυτιδίνης ενθυλακωμένου στον εν λόγω λιποσωμικό φορέα είναι χρήσιμος στην επίτευξη κατακράτησης φαρμάκου και παρατεταμένης απελευθέρωσης φαρμάκου για έκαστο θεραπευτικό παράγοντα.
CY20121100616T 2004-04-22 2012-07-10 Λιποσωμικες φαρμακοτεχνικες μορφες παραγοντων ανθρακυκλινης και αναλογων κυτιδινης CY1113012T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56521004P 2004-04-22 2004-04-22
EP05738885A EP1744764B1 (en) 2004-04-22 2005-04-22 Liposomal formulations of anthracycline agents and cytidine analogs

Publications (1)

Publication Number Publication Date
CY1113012T1 true CY1113012T1 (el) 2016-04-13

Family

ID=35196733

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20121100616T CY1113012T1 (el) 2004-04-22 2012-07-10 Λιποσωμικες φαρμακοτεχνικες μορφες παραγοντων ανθρακυκλινης και αναλογων κυτιδινης
CY2018033C CY2018033I1 (el) 2004-04-22 2018-12-07 Λιποσωμικες φαρμακοτεχνικες μορφες παραγοντων ανθρακυκλινης και αναλογων κυτιδινης

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY2018033C CY2018033I1 (el) 2004-04-22 2018-12-07 Λιποσωμικες φαρμακοτεχνικες μορφες παραγοντων ανθρακυκλινης και αναλογων κυτιδινης

Country Status (12)

Country Link
US (2) US8022279B2 (el)
EP (2) EP2407169A1 (el)
JP (1) JP4972545B2 (el)
AU (1) AU2005235455B2 (el)
CA (1) CA2564542C (el)
CY (2) CY1113012T1 (el)
ES (1) ES2388064T3 (el)
HK (1) HK1097194A1 (el)
IL (1) IL178779A (el)
NL (1) NL300960I2 (el)
PT (1) PT1744764E (el)
WO (1) WO2005102359A1 (el)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080213183A1 (en) * 2004-09-20 2008-09-04 Marcel Bally Free or Liposomal Gemcitabine Alone or in Combination with Free or Liposomal Idarubicin
WO2006126208A2 (en) * 2005-05-26 2006-11-30 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions and methods using same for delivering agents into a target organ protected by a blood barrier
ES2650167T3 (es) * 2007-02-16 2018-01-17 Celator Pharmaceuticals, Inc. Relaciones farmacológicas fijas para el tratamiento de cánceres hematopoyéticos y trastornos proliferativos
WO2009106549A2 (en) * 2008-02-26 2009-09-03 Nerviano Medical Sciences S.R.L. Antitumor combination comprising a morpholinyl anthracycline derivative and demethylating agents
WO2011119995A2 (en) 2010-03-26 2011-09-29 Cerulean Pharma Inc. Formulations and methods of use
CN101912363A (zh) * 2010-07-29 2010-12-15 蔡海德 溶解超滤-喷雾干燥-分子分散包衣-水化制粒-冷冻干燥生产脂质体组合药物
KR102284689B1 (ko) * 2011-10-21 2021-08-02 셀라토 파마슈티칼즈, 인코포레이티드 동결건조된 리포좀
RS57449B1 (sr) 2012-04-04 2018-09-28 Halozyme Inc Kombinovana terapija sa hijaluronidazom i taksanom koji ciljno deluje na tumor
JP6177885B2 (ja) 2012-05-09 2017-08-09 カンテックス ファーマシューティカルズ， インコーポレイテッド 骨髄抑制の処置
US10052346B2 (en) 2015-02-17 2018-08-21 Cantex Pharmaceuticals, Inc. Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids
JP6715265B2 (ja) 2015-05-04 2020-07-01 フェルザンティス アーゲーＶｅｒｓａｎｔｉｓ Ａｇ 膜内外ｐＨ勾配ベシクルを調製する方法
JP6564873B2 (ja) * 2015-11-02 2019-08-21 富士フイルム株式会社 リポソーム組成物およびその製造方法
IL292080B1 (en) 2015-11-11 2024-05-01 Celator Pharmaceuticals Inc Treatment regimens for hematological cancers and methods for their use
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
WO2019012328A1 (en) * 2017-07-09 2019-01-17 Biosight Pharma ANTICANCER POLY THERAPY
WO2019222435A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
US11400065B2 (en) 2019-03-01 2022-08-02 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US11980636B2 (en) 2020-11-18 2024-05-14 Jazz Pharmaceuticals Ireland Limited Treatment of hematological disorders
CN113181117B (zh) * 2021-03-22 2022-08-26 沈阳药科大学 一种紫草素和蒽环类化疗药共载脂质体及其制备方法和应用
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3993754A (en) 1974-10-09 1976-11-23 The United States Of America As Represented By The United States Energy Research And Development Administration Liposome-encapsulated actinomycin for cancer chemotherapy
US4086257A (en) 1976-10-12 1978-04-25 Sears Barry D Phosphatidyl quaternary ammonium compounds
CH624011A5 (el) 1977-08-05 1981-07-15 Battelle Memorial Institute
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4522803A (en) 1983-02-04 1985-06-11 The Liposome Company, Inc. Stable plurilamellar vesicles, their preparation and use
US4588578A (en) 1983-08-08 1986-05-13 The Liposome Company, Inc. Lipid vesicles prepared in a monophase
US5077056A (en) * 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US5736155A (en) * 1984-08-08 1998-04-07 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US5059421A (en) * 1985-07-26 1991-10-22 The Liposome Company, Inc. Preparation of targeted liposome systems of a defined size distribution
MX9203808A (es) 1987-03-05 1992-07-01 Liposome Co Inc Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos.
US5800833A (en) 1995-02-27 1998-09-01 University Of British Columbia Method for loading lipid vesicles
GB9613182D0 (en) 1996-06-24 1996-08-28 Nycomed Imaging As Method
US5837282A (en) 1996-10-30 1998-11-17 University Of British Columbia Ionophore-mediated liposome loading
US6146659A (en) * 1998-07-01 2000-11-14 Neopharm, Inc. Method of administering liposomal encapsulated taxane
ES2186484B1 (es) 2000-10-10 2004-07-01 Lipotec, S.A. Liposomas encapsulando farmacos anticancerosos y uso de los mismos en el tratamiento de tumores malignos.
US6613753B2 (en) 2001-02-21 2003-09-02 Supergen, Inc. Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
ATE475411T1 (de) * 2001-10-03 2010-08-15 Celator Pharmaceuticals Inc Liposomenladung mit metallionen
CA2383259A1 (en) * 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
CA2536612A1 (en) * 2003-04-02 2004-10-14 Celator Pharmaceuticals, Inc. Combination compositions of camptothecins and fluoropyrimidines
WO2005000266A2 (en) 2003-05-22 2005-01-06 Neopharm, Inc. Liposomal formulations comprising a combination of two or more active agents

Also Published As

Publication number Publication date
US8022279B2 (en) 2011-09-20
US20120009252A1 (en) 2012-01-12
NL300960I2 (nl) 2019-05-22
IL178779A0 (en) 2007-05-15
AU2005235455A1 (en) 2005-11-03
ES2388064T3 (es) 2012-10-08
CA2564542A1 (en) 2005-11-03
JP2007533670A (ja) 2007-11-22
WO2005102359A8 (en) 2005-12-15
US20070286897A1 (en) 2007-12-13
CY2018033I2 (el) 2019-07-10
JP4972545B2 (ja) 2012-07-11
CY2018033I1 (el) 2019-07-10
US8431806B2 (en) 2013-04-30
AU2005235455B2 (en) 2011-01-20
EP1744764A4 (en) 2009-04-01
IL178779A (en) 2013-12-31
CA2564542C (en) 2012-11-27
EP1744764B1 (en) 2012-05-30
HK1097194A1 (en) 2007-06-22
WO2005102359A1 (en) 2005-11-03
PT1744764E (pt) 2012-08-30
EP2407169A1 (en) 2012-01-18
EP1744764A1 (en) 2007-01-24

Similar Documents

Publication Publication Date Title
CY1113012T1 (el) Λιποσωμικες φαρμακοτεχνικες μορφες παραγοντων ανθρακυκλινης και αναλογων κυτιδινης
CY1116693T1 (el) Συνδυασμος αζελαστινης και κυκλεσονιδης
CY1111797T1 (el) Τοπικη φαρμακοτεχνικη μορφη ιβερμεκτινης για την θεραπεια δερματολογικων καταστασεων
DE60142890D1 (de) 3-aminoazetidinderivate enthaltende pharmazeutische zusammensetzungen, diese derivate und deren herstellung
DK1119557T3 (da) Indeno-, naphto- og benzocyclohepta-dihydrothiazolderivater, fremstilling deraf og anvendelse deraf som anorektiske medikamenter
DK1083171T3 (da) Pyrazolinderivater, deres fremstilling og anvendelse som medikamenter
BRPI0608297A2 (pt) composições de lipossomos
CO5720000A2 (es) Derivados de macrolidos con actividad antiinflamatoria, su procedimiento de sintesis y composiciones farmaceuticas que los contienen
IS2485B (is) Fenýlsúlfónýl-1,3-díhýdró-2H-indól-2-ón afleiður,framleiðsla þeirra og notkun í meðferðarskyni
CY1108544T1 (el) Παραγωγα πυραζολιου, συνθεσεις που περιεχουν τετοιες ενωσεις και μεθοδοι χρησης
NZ591802A (en) Oral and personal care compositions and methods
DK1095025T3 (da) Benzimidazoler, deres fremstilling og deres anvendelse som lægemidler
NO20014702D0 (no) Diarylderivater og deres anvendelse som medikamenter
CY1105803T1 (el) Συνθεση πepιλαμβανουσα καμπτοθεκινη και ενα παραγωγο πυριμιδινης για τη θepαπεια καρκινου
NO20052009L (no) Kombinasjonsterapi for behandling av akutt leukumi og myelodysplastikksyndrom
DK1112266T3 (da) Substituerede 4-amino-2-arylpyrimidiner, fremstilling og anvendelse deraf og farmaceutiske præparater indeholdende dem
NO20005146D0 (no) Tienylazolylalkoksyetanaminer, deres fremstilling og deres anvendelse som medikamenter
ATE426635T1 (de) Arzneimittelverabreichung
EE200200607A (et) 2-atsüülindoolderivaadid ja nende kasutamine kasvajavastaste ravimitena
UY27455A1 (es) Derivados n-(1,4,5,6-tetrahidro-ciclopentapirazol -3-il)- sustituidos. su obtención y uso como fármacos.
MA28845B1 (fr) Derives de n-(1 h-indolyl)-i h-ind0le-2-carb0xamides, leur preparation et leur application en therapeutique
AR043071A1 (es) Uso de macrolidos para el tratamiento del cancer y degeneracion macular y una composicion farmaceutica
ES2163896T3 (es) Composiciones para aumentar la concentracion y/o motilidad de los espermatozoos en humanos.
ITMI20022292A1 (it) 9a-azalidi ad attivita' antiinfiammatoria.
DK1401405T3 (da) Orale, farmaceutiske sammensætninger med forbedret biotilgængelighed